Vaccination campaigns against the coronavirus in the EU are recovering ground lost in the early days of the pandemic, although the European Commission says “we need to keep up the effort.”

Sales at the Swiss major have returned to around 80%-90% of their pre-pandemic levels, according to CFO Harry Kirsch after unveiling a healthy set of second-quarter financials.

Studies point to Johnson & Johnson, Pfizer and Bharat Biotech’s vaccines neutralizing the Delta variant of SARS-CoV-2, even if efficacy is lower compared to the original strain. This follows positive news from other vaccine companies but will the Lambda variant cause a setback?

The company could have a significant competitive position thanks to the ability to rapidly develop and combine vaccines using mRNA technology.